Compare Biocon with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON AUROBINDO PHARMA BIOCON /
AUROBINDO PHARMA
 
P/E (TTM) x 40.1 11.5 348.3% View Chart
P/BV x 5.3 1.4 373.4% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 BIOCON    AUROBINDO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-21
AUROBINDO PHARMA
Mar-21
BIOCON /
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs4881,023 47.7%   
Low Rs275333 82.4%   
Sales per share (Unadj.) Rs59.2422.8 14.0%  
Earnings per share (Unadj.) Rs7.792.0 8.4%  
Cash flow per share (Unadj.) Rs13.7110.0 12.4%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Avg Dividend yield %00.6 0.0%  
Book value per share (Unadj.) Rs62.3374.3 16.6%  
Shares outstanding (eoy) m1,200.00585.94 204.8%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x6.41.6 401.3%   
Avg P/E ratio x49.47.4 670.2%  
P/CF ratio (eoy) x27.96.2 452.1%  
Price / Book Value ratio x6.11.8 337.7%  
Dividend payout %04.3 0.0%   
Avg Mkt Cap Rs m457,350397,398 115.1%   
No. of employees `000NANA-   
Total wages/salary Rs m17,41035,350 49.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m71,058247,746 28.7%  
Other income Rs m6,0523,809 158.9%   
Total revenues Rs m77,110251,555 30.7%   
Gross profit Rs m13,14581,480 16.1%  
Depreciation Rs m7,15110,554 67.8%   
Interest Rs m577745 77.5%   
Profit before tax Rs m11,46973,990 15.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,21520,098 11.0%   
Profit after tax Rs m9,25453,892 17.2%  
Gross profit margin %18.532.9 56.2%  
Effective tax rate %19.327.2 71.1%   
Net profit margin %13.021.8 59.9%  
BALANCE SHEET DATA
Current assets Rs m76,004198,235 38.3%   
Current liabilities Rs m42,101106,652 39.5%   
Net working cap to sales %47.737.0 129.1%  
Current ratio x1.81.9 97.1%  
Inventory Days Days13719 711.7%  
Debtors Days Days6352 121.2%  
Net fixed assets Rs m106,142135,778 78.2%   
Share capital Rs m6,000586 1,024.1%   
"Free" reserves Rs m68,728218,713 31.4%   
Net worth Rs m74,728219,299 34.1%   
Long term debt Rs m29,6161,684 1,758.7%   
Total assets Rs m182,146334,013 54.5%  
Interest coverage x20.9100.3 20.8%   
Debt to equity ratio x0.40 5,161.0%  
Sales to assets ratio x0.40.7 52.6%   
Return on assets %5.416.4 33.0%  
Return on equity %12.424.6 50.4%  
Return on capital %11.533.8 34.1%  
Exports to sales %053.8 0.0%   
Imports to sales %7.216.4 43.6%   
Exports (fob) Rs mNA133,248 0.0%   
Imports (cif) Rs m5,08440,615 12.5%   
Fx inflow Rs m11,791133,248 8.8%   
Fx outflow Rs m5,08444,946 11.3%   
Net fx Rs m6,70788,302 7.6%   
CASH FLOW
From Operations Rs m11,59733,289 34.8%  
From Investments Rs m-36,2475,987 -605.4%  
From Financial Activity Rs m25,640-13,648 -187.9%  
Net Cashflow Rs m72325,831 2.8%  

Share Holding

Indian Promoters % 39.7 48.8 81.5%  
Foreign collaborators % 20.9 3.1 681.1%  
Indian inst/Mut Fund % 24.0 38.3 62.6%  
FIIs % 15.6 20.8 75.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.4 48.2 81.7%  
Shareholders   347,911 338,639 102.7%  
Pledged promoter(s) holding % 0.0 14.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    

Yellow Ad

Advertisement

A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more



Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Related Views on News

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling(Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jun 24, 2022 (Close)

TRACK BIOCON

BIOCON - DENIS CHEM LAB COMPARISON

COMPARE BIOCON WITH

MARKET STATS